Skip to main content

UMSOM Cancer Expert at Institute of Human Virology Named Fellow of American Society of Clinical Oncology

March 20, 2018 | Nora Samaranayake

Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS

Dr. Clement Adebamowo Recognized for Research in Challenging Populations and Settings

Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS, Associate Director of Population Science at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMSOM), and Professor of Epidemiology and Public Health, Institute of Human Virology, has been named a 2018 Fellow of the American Society of Clinical Oncology (ASCO).

Dr. Adebamowo will be honored at the opening session of the ASCO annual meeting on June 2, 2018 in Chicago. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO Fellows are awarded this prestigious award in recognition for their extraordinary volunteer service, dedication, and commitment to the clinical oncology association.

“Dr. Adebamowo is an extremely talented international researcher with a passion to develop quality, international clinical research studies and training opportunities,” said Kevin J. Cullen, MD, the Marlene and Stewart Greenebaum Distinguished Professor of Oncology and Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center. “His impressive track record in cancer research in complex and challenging populations and settings truly makes him a leader in the oncology field and worthy of this special award,” said Jay Magaziner, PhD, MSHyg, Department Chair of Epidemiology and Public Health.

Dr. Adebamowo received his Bachelor’s degree in Surgery and Medicine with honors from the University of Jos, Nigeria and his postgraduate surgical training at the University College Hospital, lbadan Nigeria. Upon graduation, he joined the Department of Surgery as a Lecturer 1 and advanced to Professor of Surgery at the University of lbadan, Nigeria. In 2004 he received his Sc.D. in Nutritional Epidemiology with a minor in Biostatistics from Harvard University. During his medical training and subsequent work he received multiple travel grants and was a Guest Scholar of the American College of Surgeons and the American Society of Clinical Oncology. In 2009, he joined the Institute of Human Virology, Department of Epidemiology and Prevention, Division of Cancer Epidemiology, and the Population Research Program of the University of Maryland Marlene and Stewart Greenebaum Cancer Center as an Associate Professor. In 2013 he was promoted to Professor and in 2015 he became the Associate Director of Population Science, Greenebaum Comprehensive Cancer Center.

Dr. Adebamowo has more than 200 peer-reviewed publications and three active NIH grants. His scientific contributions in the area of HPV infection epidemiology, vaginal microenvironment, cervical carcinogenesis, breast cancer, research ethics and viral genomics are highly significant and represented in his frequently cited publications. His studies are one of the few that properly characterize the molecular subtypes of breast cancer in African populations, a critical requirement for application of modern therapeutics and prognostication.  Dr. Adebamowo is also identifying barriers to cervical cancer screening and conducting research into different models of delivering HPV DNA-based vaccines in low resource and under-served communities internationally.

“Dr. Adebamowo is an integral part of our viral cancer research team,” said Robert Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine and Director, Institute of Human Virology.  “He has been laser-focused on ensuring that our viral cancer research progresses from bench to bedside in both the U.S. and Africa. I am extremely pleased that he has received this well-deserved honor.”

“Dr. Adebamowo has provided immense contributions to our cancer research here at the University of Maryland School of Medicine. His international research in low resource and under-served communities truly embodies our mission,” said E. Albert Reece, MD, PhD, MBA, University Executive Vice President of Medical Affairs and the John Z. and Akiko K. Bowers Distinguished Professor and Dean at the University of Maryland School of Medicine.

About the Institute of Human Virology

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information, www.ihv.org and follow us on Twitter @IHVmaryland.

About the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center in Baltimore. The center is a joint entity of the University of Maryland Medical Center and University of Maryland School of Medicine. It offers a multidisciplinary approach to treating all types of cancer and has an active cancer research program. It is ranked among the top cancer programs in the nation by U.S. News & World Report. www.umgccc.org

About the University of Maryland School of Medicine

Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact in excess of $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/

Contact

Institute of Human Virology
Nora Samaranayake
Director of Marketing and Public Relations
(410) 706-8614 (phone)
(410) 706-1952 (fax)
nsamaranayake@ihv.umaryland.edu

Related stories

    Wednesday, September 19, 2018

    Institute of Human Virology (IHV) Awarded $12M to Combat Opioid Epidemic Through Clinical Research Trials

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine will lead a $12 million dollar project to improve the morbidity and mortality of people with opioid use disorder (OUD). Utilizing a novel compound, IHV researches will implement a series of investigations, entitled SEARCH, to evaluate the underlying mechanisms of craving reduction as a strategy to prevent opioid misuse, dependence, and relapse. The grant is awarded through the National Institutes of Health’s (NIH) Helping to End Addiction Long-term (HEAL) Initiative, made possible through groundbreaking funding from the U.S. Congress.


    Wednesday, March 21, 2018

    Dr. Robert Redfield, Co-Founder of the Institute of Human Virology at the University of Maryland School of Medicine, to Become CDC Director

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) congratulates its co-founder and associate director, Robert R. Redfield, MD, on his appointment to be the next director of the U.S. Centers for Disease Control and Prevention (CDC).


    Tuesday, November 22, 2016

    IHV Awarded $138M to combat HIV/AIDS in Africa & Launches Center for International Health, Education, & Biosecurity

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today more than $138 million in multiple five-year grants awarded by the Centers for Disease Control and Prevention to combat HIV/AIDS in Kenya, Tanzania, Zambia, and Nigeria. The Institute concurrently announced the formation of the IHV Center for International Health, Education, & Biosecurity (CIHEB), and its newly appointed director, Deus Bazira Mubangizi, DrPH, MBA, MPH, Assistant Professor of Medicine, Director, Center for Health, Education, & Biosecurity, Institute of Human Virology, University of Maryland School of Medicine.


    Wednesday, April 13, 2016

    IHV Releases Data Supporting Community-Based Treatment Providers in Fight Against Hepatitis C

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine released data today at The International Liver Congress 2016 in Barcelona, Spain demonstrating that treatment for hepatitis C virus (HCV) can be provided safely and effectively within a community-based and non-specialist setting.


    Tuesday, December 01, 2015

    A Statement from the Leadership of the Institute of Human Virology on World AIDS Day

    Research enabled treatment to be developed for HIV/AIDS, allowing the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (which Dr. Gallo heads and co-founded with his colleagues Drs. William Blattner and Robert Redfield) to develop a promising HIV vaccine candidate, treat nearly 6,000 patients annually in Baltimore, and care for more than 1 million people in Africa and the Caribbean since 2004.


    Tuesday, September 29, 2015

    Institute of Human Virology Hosts International Meeting of Prominent AIDS Researchers

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine is hosting IHV’s 17th Annual International Meeting Sunday, September 27 through Wednesday, September 30 at the Baltimore Marriott Waterfront Hotel in Baltimore, Maryland.


    Tuesday, June 23, 2015

    Institute of Human Virology (IHV) Awarded $24.5M to Fight Botswana’s AIDS Epidemic

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine has received a five-year $24.5 million grant from the U.S. Centers for Disease Control and Prevention (CDC) through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to partner with the Government of Botswana and impact the HIV/AIDS epidemic in Botswana, and to demonstrate that comprehensive HIV/AIDS treatment programs can stop the epidemic. PEPFAR is a $48 billion initiative launched in 2004 by former President George W. Bush, and continued by President Barack Obama, to combat major infectious diseases around the world, including HIV.